Search
Keros Therapeutics Inc
KROSAdd to Watchlist
11.550USD
-0.080-0.69%
Close 09-23 16:00（ET）
228.57MMarket Cap
LossP/E TTM
Keros Therapeutics Inc (KROS) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Keros Therapeutics Inc in the past month.
Buy
1 Strong Buy
3 Buy
3 Hold
0 Sell
0 Strong Sell
Target Price
19.800USD+70.25%
KROS Analyst Recommendation Trends
In the current month, KROS has received 3 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. KROS average Analyst price target in the last month is 19.800.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
2
2
2
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
8
8
9
9
9
10
KROS Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, KROS EPS is projected to reach -0.940 in FY2026Q3, following reported EPS of -1.450 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.63
-1.02
-1.34
-0.94
-1.93
Actual
-0.87
-1.21
-1.45
--
--
Surprise
-37.75%
-18.08%
-8.21%
--
--
FAQs
What is Keros Therapeutics Inc's expected revenue for the next quarter?
Keros Therapeutics Inc's expected revenue is 14.76M.
What is Keros Therapeutics Inc's price target?
Analysts forecast that Keros Therapeutics Inc's price target is USD 19.80, with the highest forecast at USD 25.00 and the lowest forecast at USD 16.00.
How have Keros Therapeutics IncKROS's recent earnings per share performed?
The market expectation was USD -1.45, while Keros Therapeutics IncKROS's earnings per share (EPS) for the previous quarter was USD -1.21. EPS for the next quarter is expected at USD -0.94.
What is the analyst rating for Keros Therapeutics Inc?
Based on the ratings of Keros Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.